Tobacco Dependence Clinical Trial
Official title:
A Single Dose, Randomized, Four Period, Fasting, Crossover Study to Assess Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Mint Gum 2 and 4 mg - in Adult Healthy Male and Female Smokers
This is a research study to verify the same effectiveness and safety profile for the test
products, nicotine 2 mg gum and nicotine 4 mg gum, as for the already approved products,
Nicorette Mint 2 mg gum and Nicorette Mint 4 mg gum (reference products), in a standardized
mode. This verification is done in a so-called bioequivalence study, which means that the
same amount of the same active substance (nicotine), in the same dosage form, for the same
route of administration, and meeting the same or comparable standards is performed.
During the study visits, blood samples will be drawn to measure the level of the substance in
the blood to verify that the two test products are comparable to the reference products.
Tolerability of the treatments will be evaluated based on reported and observed adverse
events.
This is a single-center, randomized, single-dose open-label, cross-over study in 76 healthy
males and females in total. The investigational products (IPs), i.e., Nicorette Extra Mint
Gum 2 and 4 mg, and Nicorette Mint Gum 2 and 4 mg, will be given as single doses at separate
treatment visits. Investigational treatments will be separated by at least 36 hours.
Blood samples for determination of nicotine will be drawn pre-dose (within 5 minutes of
administering, i.e., start of chewing) and at 5, 10, 15, 20, 30, 45, and 60 minutes, as well
as 1.5, 2, 4, 6, 7, 8, 9, and 10 hours after start of administration.
Used gums will be collected and analyzed to determine the amount of remaining nicotine.
Any Adverse Events (AEs) that may occur will be registered.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01928719 -
Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
|
N/A | |
Completed |
NCT01995123 -
Behavioral Activation for Smoking Cessation in PTSD
|
N/A | |
Not yet recruiting |
NCT03249428 -
E-Cigarette Inner City RCT
|
N/A | |
Recruiting |
NCT02564289 -
Cardiovascular Effects of Chronic Snus Use
|
N/A | |
Completed |
NCT01928758 -
Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
|
N/A | |
Withdrawn |
NCT01847300 -
cSBI-M for Young Military Personnel
|
N/A | |
Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
Recruiting |
NCT00977249 -
Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00968513 -
Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
|
Phase 3 | |
Completed |
NCT00747643 -
Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
|
N/A | |
Completed |
NCT00722124 -
S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
|
Phase 2/Phase 3 | |
Completed |
NCT01113424 -
Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum
|
N/A | |
Completed |
NCT01238627 -
Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg
|
N/A | |
Completed |
NCT01228617 -
Single-dose Pharmacokinetics of Oral Nicotine Replacement Products
|
N/A | |
Completed |
NCT00296647 -
Smoking Cessation Intervention: Effectiveness in Primary Care
|
Phase 4 | |
Completed |
NCT00394420 -
Emergency Department Telephone Quitline
|
N/A | |
Recruiting |
NCT05487807 -
Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia
|
Phase 1 | |
Completed |
NCT03553992 -
An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers
|
N/A | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A |